{"id":2194,"date":"2014-07-10T19:46:33","date_gmt":"2014-07-10T19:46:33","guid":{"rendered":"http:\/\/skinnygeneproject.dreamhosters.com\/?p=2194"},"modified":"2014-07-10T19:46:33","modified_gmt":"2014-07-10T19:46:33","slug":"skinny-gene-project-freedom-meditech-partnership-will-revolutionize-healthcare-screenings","status":"publish","type":"post","link":"https:\/\/www.skinnygeneproject.org\/skinny-gene-project-freedom-meditech-partnership-will-revolutionize-healthcare-screenings\/","title":{"rendered":"New Partnership Revolutionizes Prediabetes Screenings"},"content":{"rendered":"

The Skinny Gene Project has partnered with Freedom Meditech, a medical device company, to provide a revolutionary new kind of prediabetes healthcare screening. The Clearpath DS-120 is an FDA approved device that is non-invasive and has immediate results. Compared to other diabetes screenings, the Clearpath DS-120 does not involve drawing blood, or any discomfort for the patient.<\/p>\n

\"ClearPath_DS_120\"<\/p>\n

97% of people with prediabetes are unaware they have this condition.<\/strong><\/em>\u00a0By partnering with Freedom Meditech, our goal is to change this statistic.” – Marlayna Bolinger, Executive Director of the Skinny Gene Project<\/p><\/blockquote>\n

Screening for Prediabetes<\/h3>\n

Currently, 79 million Americans<\/strong> have a condition known as prediabetes, which generally precedes type 2 diabetes.\u00a0People with prediabetes have blood sugar levels that are higher than normal, but not high enough for a diagnosis of diabetes. They are at higher risk for developing type 2 diabetes and other serious health problems, including heart disease, and stroke. Without lifestyle changes<\/a> to improve their health, people with prediabetes will most likely develop full-blown type 2 diabetes within 5 – 7 years.<\/p>\n

Since prediabetes and type 2 diabetes have no noticeable symptoms, \u00a0the disease is \u00a0commonly\u00a0only diagnosed several years after its onset, when complications are already present. \u00a0The Clearpath DS-120 has the ability to detect prediabetes and early diabetes up to 7 years before complications begin<\/strong>. \u00a0Once a person’s\u00a0risk has been determined, they can go to their primary care provider for a formal diagnosis.\u00a0This information\u00a0gives a person the opportunity to take the necessary actions to prevent the further development of type 2 diabetes and begin to restore their health.<\/p>\n

The Clearpath DS-120 is revolutionizing prediabetes and early diabetes screenings, because with a 6\u00a0second, painless scan of the eye, a person will be able to\u00a0understand their risk. Then, they have options on how to proceed. That’s putting the power of prevention back into the hands of the people.<\/p>\n

Through the partnership, the\u00a0Skinny Gene Project and Freedom Meditech are providing pre and post-screening education materials to be distributed to patients, including a “Next Steps” brochure to direct those at-risk to the appropriate professionals. \u00a0In San Diego, CA, the two organizations work together to provide prediabetes screenings in low-income communities that have an increased risk for diabetes.<\/p>\n

Detecting Prediabetes<\/h3>\n

How does it work? The Clearpath DS-120 detects prediabetes by scanning the crystalline lens of the eye with a blue light to measure autofluorescence. Studies have shown that elevated\u00a0autofluorescence measurements can be an indicator of\u00a0glucose control,\u00a0the body’s aging process and the\u00a0presence of systemic disease.<\/p>\n

Being able to\u00a0identify risks of diabetes 7 years prior to complications is crucial in helping to detect and treat diabetes before it can affect an individual\u2019s quality of life. Together, Skinny Gene Project and Freedom Meditech want to inform the public about the benefits of the Clearpath DS-120 and how its use will aid in diagnosing \u00a0undetected prediabetes and diabetes early on.<\/p>\n

Since the first symptoms of diabetes to appear are usually related to the eye, the Clearpath DS-120 will be useful as part of a yearly check up at the eye doctor. The device could easily be implemented under a\u00a0professional’s care during each visit, in addition to screenings for glaucoma and retinopathy.<\/p>\n

By including the\u00a0Clearpath DS-120\u00a0in Optometrist and Ophthalmologist offices, where patients receive an annual eye exam,\u00a0we are not just increasing early detection screenings; we’re increasing the opportunity to prevent diabetes.<\/p>\n

For more information about Freedom Meditech and their mission you can visit their website at: www.freedom-meditech.com.<\/p>\n

About Skinny Gene Project<\/h3>\n

The Skinny Gene Project (a division of the J.Moss Foundation) is a 501(c)(3) non-profit organization dedicated to preventing diabetes. We help educate those who are at-risk; empower them with the resources, tools, and support needed to make healthy lifestyle changes; and teach them how to make the long-term social, environment, and behavioral changes needed to prevent the onset of type 2 diabetes.<\/p>\n

If you at-risk for diabetes, please contact us<\/a> today to see how we can help!<\/p>\n","protected":false},"excerpt":{"rendered":"

The Skinny Gene Project has partnered with Freedom Meditech, a medical device company, to provide a revolutionary new kind of prediabetes healthcare screening. The Clearpath DS-120 is an FDA approved device that is non-invasive and has immediate results. Compared to other diabetes screenings, the Clearpath DS-120 does not involve drawing blood, or any discomfort for… <\/p>\n

<\/div>\n

Read More<\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false}}},"categories":[1462,222,1],"tags":[1065,1469,1470,471,304,73,74,1471,78,218,82,83,445,446],"jetpack_publicize_connections":[],"acf":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p90Iz0-zo","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/www.skinnygeneproject.org\/wp-json\/wp\/v2\/posts\/2194"}],"collection":[{"href":"https:\/\/www.skinnygeneproject.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.skinnygeneproject.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.skinnygeneproject.org\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.skinnygeneproject.org\/wp-json\/wp\/v2\/comments?post=2194"}],"version-history":[{"count":0,"href":"https:\/\/www.skinnygeneproject.org\/wp-json\/wp\/v2\/posts\/2194\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.skinnygeneproject.org\/wp-json\/wp\/v2\/media?parent=2194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.skinnygeneproject.org\/wp-json\/wp\/v2\/categories?post=2194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.skinnygeneproject.org\/wp-json\/wp\/v2\/tags?post=2194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}